Custom mRNA vaccine takes on rare endocrine cancers

NCT ID NCT06141369

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a personalized mRNA vaccine (mRNA-0523-L001) for people with advanced endocrine tumors like adrenal cancer, medullary thyroid cancer, and pancreatic neuroendocrine tumors who have no standard treatment left. The vaccine is made to target unique mutations in each person's tumor. The main goals are to see if the vaccine is safe and tolerable, and to check if it triggers an immune response against the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell adrenal carcinoma adrenal cortex carcinoma Carcinoma, Medullary familial medullary thyroid carcinoma medullary thyroid gland carcinoma pancreatic neuroendocrine tumor thymic neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin hospital, Shanghai Jiao-Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact